InSite Vision to Present at Rodman & Renshaw 12th Annual Healthcare Conference

ALAMEDA, Calif.--(BUSINESS WIRE)-- InSite Vision Incorporated (OTCBB: INSV), a company developing novel ophthalmic therapeutics, announced today that Louis Drapeau, Interim Chief Executive Officer, Vice President and Chief Financial Officer, will present a corporate overview at the upcoming Rodman & Renshaw 12th Annual Healthcare Conference. The conference is being held September 12-15, 2010 at the New York Palace Hotel in New York City.

Mr. Drapeau’s presentation is scheduled for Monday, September 13, 2010 at 10:50 am EDT. Mr. Drapeau will discuss InSite’s commercial products and partnerships; the company’s proprietary DuraSite® bioadhesive polymer platform technology; and InSite’s emerging pipeline, including the recent advancement of ISV-303 into Phase 1/2 clinical trials for the treatment of ocular pain.

The presentation will also be webcast and available on the Investor Relations page of the company's website at www.insitevision.com. The presentation will be archived for replay at the same address one hour after conclusion of the live event for a period of 30 days.

About InSite Vision

InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. The company’s product portfolio utilizes InSite Vision’s proven DuraSite® bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Inspire Pharmaceuticals, and Besivance™ (besifloxacin ophthalmic suspension) 0.6%, marketed by InSite Vision’s licensee Bausch & Lomb and their partner Pfizer Inc. InSite Vision’s clinical-stage ophthalmic product pipeline includes ISV-502 and ISV-305 for the treatment of eye infections, and ISV-303 for pain and swelling associated with ocular surgery. For further information on InSite Vision, please visit www.insitevision.com.



CONTACT:

InSite Vision
Louis Drapeau, 510-747-1220
Interim Chief Executive Officer and
Vice President, Chief Financial Officer
[email protected]
or
BCC Partners
Media/Investor Inquiries
Michelle Corral, 415-794-8662

KEYWORDS:   United States  North America  California  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases  Optical  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.

Danish drugmaker Novo Nordisk is opening up its bleeding disorder trials five months after they were stopped.